Premium
Treatment of Advanced Bladder Cancer with Adriamycin and 5‐Fluorouracil
Author(s) -
CROSS R. J.,
GLASHAN R. W.,
HUMPHREY C. S.,
ROBINSON M. R. G.,
SMITH P. H.,
WILLIAMS R. E.
Publication year - 1976
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1976.tb06708.x
Subject(s) - bladder cancer , fluorouracil , medicine , oncology , chemotherapy , cancer , doxorubicin , drug , chemotherapeutic drugs , toxicity , pharmacology
Summary The cytotoxic drug combination of adriamycin and 5‐fluorouracil has resulted in a 35% objective response in 20 patients with advanced bladder cancer. This has been achieved with minimal toxicity and on an out‐patient basis. If the survival rate of patients with invasive bladder cancer is to be improved it seems likely that some form of systemic treatment will need to be added to the local measures currently in use. Further studies of different chemotherapeutic agents should help to define an effective and safe form of adjunvant therapy. We should like to acknowledge the financial assistance given to us by the Yorkshire Regional Cancer Organisation without which this study would have been impossible. This work is part of a pilot study carried out by the E.O.R.T.C. Urological Group.